Design of targeted cardiovascular molecular imaging probes

Journal of Nuclear Medicine

Volumn 51, Issue SUPPL.1, 2010, Pages

  Anderson, Carolyn J ^a   Bulte, Jeff W M ^b   Chen, Kai ^c   Chen, Xiaoyuan ^c   Khaw, Ban An ^d   Shokeen, Monica ^a   Wooley, Karen L ^e,f   VanBrocklin, Henry F ^g  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NORTHEASTERN UNIVERSITY   (United States)

^e TEXAS A AND M UNIVERSITY   (United States)

^f Texas AandM University   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bispecific antibodies; Molecular imaging; Multimeric molecular imaging agents; Nanomaterials; Nanoparticles; Superparamagnetic iron oxide

Indexed keywords

CARBON 11; CELL PROTEIN; FLUORINE 18; GADOLINIUM; IRON OXIDE; NANOPARTICLE; RADIOISOTOPE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ANTIBODY; FERRIC ION; FERRIC OXIDE; METAL NANOPARTICLE;

ATHEROSCLEROTIC PLAQUE; CELL LABELING; CELL SURFACE; CELL THERAPY; CORONARY ARTERY DISEASE; ENZYME SUBSTRATE; GENOMICS; HEART INFARCTION; HUMAN; ISCHEMIA; MOLECULAR IMAGING; MOLECULAR PROBE; MONITORING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; CELL MEMBRANE; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; DENDRITIC CELL; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY; EQUIPMENT DESIGN; METABOLISM; METHODOLOGY; NANOTECHNOLOGY; POSITRON EMISSION TOMOGRAPHY;

ANIMALS; ANTIBODIES; CELL MEMBRANE; DENDRITIC CELLS; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY; EQUIPMENT DESIGN; FERRIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE IMAGING; METAL NANOPARTICLES; MOLECULAR PROBES; NANOTECHNOLOGY; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; SOFTWARE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77953075333     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.068130     Document Type: Review

References (66)

1. Long CM, Bulte JW. In vivo tracking of cellular therapeutics using magnetic resonance imaging. Expert Opin Biol Ther. 2009;9:293-306.
2. Bulte JW. In vivo MRI cell tracking: clinical studies. AJR. 2009;193:314-325.
3. de Vries IJ, Lesterhuis WJ, Barentsz JO, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol. 2005;23:1407-1413.
4. Long CM, van Laarhoven HW, Bulte JW, Levitsky HI. Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes. Cancer Res. 2009;69:3180-3187.
5. Frank JA, Miller BR, Arbab AS, et al. Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology. 2003;228:480-487.
6. Walczak P, Kedziorek DA, Gilad AA, Lin S, Bulte JW. Instant MR labeling of stem cells using magnetoelectroporation. Magn Reson Med. 2005;54:769-774.
7. Anderson SA, Lee KK, Frank JA. Gadolinium-fullerenol as a paramagnetic contrast agent for cellular imaging. Invest Radiol. 2006;41:332-338.
8. Trattnig S, Pinker K, Ba-Ssalamah A, Nöbauer-Huhmann IM. The optimal use of contrast agents at high field MRI. Eur Radiol. 2006;16:1280-1287.
9. Thomsen HS, Marckmann P, Logager VB. Update on nephrogenic systemic fibrosis. Magn Reson Imaging Clin N Am. 2008;16:551-560.
10. McMahon MT, Gilad AA, DeLiso MA, Berman SM, Bulte JW, van Zijl PC. New "multicolor" polypeptide diamagnetic chemical exchange saturation transfer (DIACEST) contrast agents for MRI. Magn Reson Med. 2008;60:803-812.
11. Gilad AA, McMahon MT, Walczak P, et al. Artificial reporter gene providing MRI contrast based on proton exchange. Nat Biotechnol. 2007;25:217-219.
12. Ahrens ET, Flores R, Xu H, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol. 2005;23:983-987.
13. Bulte JW. Hot spot MRI emerges from the background. Nat Biotechnol. 2005;23:945-946.
14. Partlow KC, Chen J, Brant JA, et al. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J. 2007;21:1647-1654.
15. Ruiz-Cabello J, Walczak P, Kedziorek DA, et al. In vivo "hot spot" MR imaging of neural stem cells using fluorinated nanoparticles. Magn Reson Med. 2008;60:1506-1511.
16. Barnett BP, Kraitchman DL, Lauzon C, et al. Radiopaque alginate microcapsules for X-ray visualization and immunoprotection of cellular therapeutics. Mol Pharm. 2006;3:531-538.
17. Barnett BP, Arepally A, Karmarkar PV, et al. Magnetic resonance-guided, real-time targeted delivery and imaging of magnetocapsules immunoprotecting pancreatic islet cells. Nat Med. 2007;13:986-991.
18. 18F-2-deoxy-2-fluoro-D- glucose. J Nucl Med. 1978;19:1154-1161.
19. Ghesani M, Depuey EG, Rozanski A. Role of F-18 FDG positron emission tomography (PET) in the assessment of myocardial viability. Echocardiography. 2005;22:165-177.
20. Segall G. Assessment of myocardial viability by positron emission tomography. Nucl Med Commun. 2002;23:323-330.
21. Slart RH, Bax JJ, van Veldhuisen DJ, van der Wall EE, Dierckx RA, Jager PL. Imaging techniques in nuclear cardiology for the assessment of myocardial viability. Int J Cardiovasc Imaging. 2006;22:63-80.
22. Bengel FM. Atherosclerosis imaging on the molecular level. J Nucl Cardiol. 2006;13:111-118.
23. Beeres SL, Bengel FM, Bartunek J, et al. Role of imaging in cardiac stem cell therapy. J Am Coll Cardiol. 2007;49:1137-1148.
24. 18F]galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem. 2004;15:61-69.
25. 18F]galacto-RGD. PLoS Med. 2005;2:e70.
26. Haubner R, Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des. 2004;10:1439-1455.
27. Higuchi T, Bengel FM, Seidl S, et al. Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res. 2008;78:395-403.
28. 18F-labelled annexin V: a PET tracer for apoptosis imaging. Eur J Nucl Med Mol Imaging. 2004;31:469-474.
29. 11C]-(-)-phenylephrine as a functional heart neuronal PET agent. Nucl Med Biol. 1996;23:611-616.
30. 11C]hydroxyephedrine and positron emission tomography. Circulation. 2000;101:516-523.
31. 11C]hydroxyephedrine, a specific tracer for sympathetic nerve endings, and its functional correlates in congestive heart failure. Am J Cardiol. 1999;84:568-574.
32. 11C-heptadecanoic acid for measurement of myocardial fatty acid metabolism. J Nucl Med. 2002;43:1707-1714.
33. Schelbert HR, Benson L, Schwaiger M, Perloff J. Positron emission tomography: the technique and its applications to the study of the cardiovascular system. Cardiol Clin. 1983;1:501-520.
34. Schelbert HR, Henze E, Keen R, et al. C-11 palmitate for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron-computed tomography. IV. In vivo evaluation of acute demand-induced ischemia in dogs. Am Heart J. 1983;106:736-750.
35. Schön HR, Schelbert HR, Najafi A, et al. C-11 labeled palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron-computed tomography. II. Kinetics of C-11 palmitic acid in acutely ischemic myocardium. Am Heart J. 1982;103:548-561.
36. Buck A, Wolpers HG, Hutchins GD, et al. Effect of carbon-11-acetate recirculation on estimates of myocardial oxygen consumption by PET. J Nucl Med. 1991;32:1950-1957.
37. Buxton DB, Schwaiger M, Nguyen A, Phelps ME, Schelbert HR. Radiolabeled acetate as a tracer of myocardial tricarboxylic acid cycle flux. Circ Res. 1988;63:628-634.
38. 11C]GB67, a novel radioligand for imaging myocardial alpha 1-adrenoceptors with positron emission tomography. Eur J Nucl Med. 2000;27:7-17.
39. Sun X, Anderson CJ. Production and applications of copper-64 radiopharmaceuticals. Methods Enzymol. 2004;386:237-261.
40. Rodriguez-Porcel M, Cai W, Gheysens O, et al. Imaging of VEGF receptor in a rat myocardial infarction model using PET. J Nucl Med. 2008;49:667-673.
41. +. J Nucl Med. 1993;34:1127-1131.
42. 68Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta(3) expression. Eur J Nucl Med Mol Imaging. 2008;35:1100-1108.
43. Brennan M, Davison PF, Paulus H. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science. 1985;229:81-83.
44. 99mTc-labeled negatively charged polymers. J Nucl Med. 2006;47:868-876.
45. Khaw BA. Antibodies: considerations for in vitro and in vivo applications. In: Khaw BA, Narula J, Strauss HW, eds. Monoclonal Antibodies in Cardiovascular Diseases. Philadelphia, PA: Lea &Febiger, a Waverly Co.; 1994:1-12.
46. Khaw BA, Gold HK, Yasuda T, et al. Scintigraphic quantification of myocardial necrosis in patients after intravenous injection of myosin-specific antibody. Circulation. 1986;74:501-508.
47. Khaw BA, Yasuda T, Gold HK, et al. Acute myocardial infarct imaging with indium-111-labeled monoclonal antimyosin Fab. J Nucl Med. 1987;28:1671-1678.
48. Patil V, Pincus D, Keyur G, et al. Molecular imaging of lung metastatic melanoma with bispecific antibody and Tc-99m labeled polymers: signal amplification allows visualization of very small lesion. Paper presented at: World Molecular Imaging Congress; September 10-13, 2008; Nice, France.
49. Gada K, Patil V, Khaw B, et al. Enhanced targeted tumorotoxicity and reduced cardiotoxicity with bispecific antibody-polymer-prodrug complexes: in vitro studies with BT-20 human breast carcinoma and embryonic cardiocytes. Poster presented at: 35th Annual Meeting & Exposition of the Controlled Release Society; July 13-16, 2008; New York, NY.
50. Vasey PA, Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res. 1999;5:83-94.
51. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 1986;46:6387-6392.
52. Almutairi A, Rossin R, Shokeen M, et al. Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc Natl Acad Sci USA. 2009;106:685-690.
53. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2007;24:1-16.
54. ElBayoumi TA, Torchilin VP. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res. 2009;15:1973-1980.
55. Park JS, Na K, Woo DG, et al. Non-viral gene delivery of DNA polyplexed with nanoparticles transfected into human mesenchymal stem cells. Biomaterials. 2010;31:124-132.
56. Glickson JD, Lund-Katz S, Zhou R, et al. Lipoprotein nanoplatform for targeted delivery of diagnostic and therapeutic agents. Adv Exp Med Biol. 2009;645:227-239.
57. Nahrendorf M, Zhang H, Hembrador S, et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation. 2008;117:379-387.
58. Prato M, Kostarelos K, Bianco A. Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res. 2008;41:60-68.
59. Jeon SI, Andrade JD. Protein-surface interactions in the presence of polyethylene oxide. II. Effect of protein size. J Colloid Interface Sci. 1991;142:159-166.
60. Jeon SI, Lee JH, Andrade JD, De Gennes PG. Protein-surface interactions in the presence of polyethylene oxide. I. Simplified theory. J Colloid Interface Sci. 1991;142:149-158.
61. Sun G, Hagooly A, Xu J, et al. Facile, efficient approach to accomplish tunable chemistries and variable biodistributions for shell cross-linked nanoparticles. Biomacromolecules. 2008;9:1997-2006.
62. Sun G, Xu J, Hagooly A, et al. Strategies for optimized radiolabeling of nanoparticles for in vivo PET imaging. Adv Mater. 2007;19:3157-3162.
63. Devaraj NK, Keliher EJ, Thurber GM, Nahrendorf M, Weissleder R. F-18-labeled nanoparticles for in vivo PET-CT imaging. Bioconjug Chem. 2009;20:397-401.
64. Lee HY, Li Z, Chen K, et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med. 2008;49:1371-1379.
65. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91-100.
66. 64Cu-labeled nanoparticles comprised of amphiphilic block graft copolymers. Biomacromolecules. 2007;8:3126-3134.